Itt Stock News

ITT Inc. (NYSE:ITT) declared a quarterly dividend on Wednesday, October 13th, RTT News reports. Shareholders of record on Monday, December 13th will be given a dividend of 0.22 per share by the conglomerate on Thursday, December 30th. This represents a $0.88 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is []

ITT (NYSE:ITT) was upgraded by stock analysts at Bank of America from a neutral rating to a buy rating in a research report issued on Wednesday, The Fly reports. A number of other research firms also recently issued reports on ITT. Citigroup increased their target price on shares of ITT from $111.00 to $116.00 and []

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

ITT (ITT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ITT (ITT) reported earnings 30 days ago. What's next for the stock?

Delcath Systems Inc (NASDAQ: DCTH ) has announced results from the Phase 3 FOCUS study of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma. The FOCUS study''s intent-to-treat (ITT) population included 102 subjects. Of the ITT group, 91 evaluable patients were administered at least one study treatment. The ITT analysis resulted in an objective response rate (ORR) of 31.4%, including 6.9% of patients with a complete response (CR) for Hepzato treatment. The median duration of Full story available on Benzinga.com

ITT Inc. (NYSE:ITT) shares saw an uptick in trading volume on Thursday . 35,048 shares changed hands during trading, a decline of 92% from the previous sessions volume of 436,489 shares.The stock last traded at $93.92 and had previously closed at $94.58. A number of research firms have weighed in on ITT. KeyCorp increased their []

On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months While overall survival data continues to mature, a Hazard Ratio (HR) analysis of survival at 12-months yielded a statistically significant advantage for HEPZATO over a Best Alternative Care (BAC) arm [HR=0.37, p=0.01] in patients who received one or more treatments HEPZATO had statistically significant improvements over BAC in predefined exploratory analyses on ORR, DCR and PFS NDA resubmission for HEPZATO expected by mid-2022 NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced positive results from the phase 3 FOCUS study. The FOCUS study''s intent-to-treat (ITT) population was comprised of a total of 102 subjects, across various lines of therapy. Of the ITT group, 91 evaluable patients were administered at least one study treatment.

ITT Inc. found using ticker (ITT) have now 11 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 120 and 95 with the average target price sitting at 111.27. Given that the stocks previous close was at 94.58 this is indicating there is a potential upside of 17.6%. The day 50 moving average is 94.99 and the 200 moving average now moves to 92.95. The market capitalisation for the company is $8,040m. Company Website: /> [stock_market_widget type="chart" symbol="ITT" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] ITT Inc. manufactures and sells engineered critical components and customized technology solutions for the energy, transportation, and industrial markets worldwide. The company operates through three segments: Motion Technologies, Industrial Process, and Connect & Control Technologies. The Motion Technologies segment manufactures brake pads, shims, shock absorbers, and energy absorption components; and sealing technologies primarily for the transportation industry, including passenger cars, light- and heavy-duty commercial and military vehicles, buses, and rail.

Brokerages expect ITT Inc. (NYSE:ITT) to report $1.05 earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for ITTs earnings. The highest EPS estimate is $1.06 and the lowest is $1.05. ITT reported earnings of $1.01 per share during the same quarter last year, which would indicate []

ITT Inc. found using ticker (ITT) have now 11 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 120 and 95 calculating the average target price we see 111.27. Now with the previous closing price of 103.42 this would indicate that there is a potential upside of 7.6%. The 50 day moving average now sits at 94.13 and the 200 moving average now moves to 92.54. The market capitalisation for the company is $8,807m. Visit the company website at: /> [stock_market_widget type="chart" symbol="ITT" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] ITT Inc. manufactures and sells engineered critical components and customized technology solutions for the energy, transportation, and industrial markets worldwide. The company operates through three segments: Motion Technologies, Industrial Process, and Connect & Control Technologies. The Motion Technologies segment manufactures brake pads, shims, shock absorbers, and energy absorption components; and sealing technologies primarily for the transportation industry, including passenger cars, light- and heavy-duty commercial and military vehicles, buses, and rail.

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- The centrifugal water pump market is set to grow by USD 7.40 billion, progressing at a CAGR of 5.34% from 2020 to 2025. CIRCOR International Inc., Ebara Corp., Flowserve Corp., Grundfos Holding AS, ITT Inc., KSB SE, and Co. KGaA, Sulzer Ltd., The

Qurates most recent research report on Water was performed by extremely qualified research professionals and business experts in order to provide an in-depth assessment on the market. The study on Water is extensive and consist of over 120 pages. The

BRRAY vs. ITT: Which Stock Is the Better Value Option?

ITT, Inc. (ITT) CEO Luca Savi on Q3 2021 Results - Earnings Call Transcript